American Century Companies Inc. lowered its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 14.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,744 shares of the biotechnology company’s stock after selling 5,896 shares during the period. American Century Companies Inc. owned 0.08% of Seres Therapeutics worth $381,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in MCRB. Teachers Advisors LLC raised its stake in shares of Seres Therapeutics by 43.5% during the 4th quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after purchasing an additional 12,462 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Seres Therapeutics by 33.7% during the 1st quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 4,829 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Seres Therapeutics by 1.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 279 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% during the 1st quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after purchasing an additional 50,860 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Seres Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 727 shares in the last quarter. Institutional investors own 74.76% of the company’s stock.

Shares of Seres Therapeutics, Inc. (MCRB) opened at 15.02 on Wednesday. Seres Therapeutics, Inc. has a 1-year low of $8.86 and a 1-year high of $15.41. The company has a 50-day moving average price of $14.64 and a 200-day moving average price of $14.64. The company’s market cap is $608.49 million.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.70) EPS. Equities research analysts expect that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “American Century Companies Inc. Has $381,000 Stake in Seres Therapeutics, Inc. (MCRB)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/20/american-century-companies-inc-has-381000-stake-in-seres-therapeutics-inc-mcrb.html.

A number of equities research analysts have recently issued reports on the company. BidaskClub cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a research note on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.